YU10 – BE PART OF OUR ANNIVERSARY
On December 3, 2012, Thomas Schirrmann founded the YUMAB GmbH as a spin-off of the University of Braunschweig together with phage display pioneer Stefan Dübel and the scientists André Frenzel and Michael Hust. Their vision was to advance antibody-based drug discovery with services for biotech and pharma R&D based on a unique technology platform. Since then, YUMAB has become a global player in the market for therapeutic antibody discovery and engineering.
Team YUMAB will celebrate the 10th anniversary throughout 2022 by sharing stories of major achievements, business, people, locations, and science with you on this website and we invite you to participate in our activities:
How do you remember YUMAB’s early years? What is your relationship to the company or the people? What’s so typical “YUMAB” that would fit to no other company? What is your message to the team? Please feel free to share memories, anecdotes and pictures with us.